Obstructed labor and caesarean delivery: the cost and benefit of surgical intervention.
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2012-01-01
Source Title
PLoS ONE
Journal Title
Journal ISSN
Volume Title
Publisher
PUBLIC LIBRARY SCIENCE
Melbourne Authors
Affiliation
Paediatrics (RCH)
Document Type
Journal Article
Subject Code
Citation
Alkire, B. C., Vincent, J. R., Burns, C. T., Metzler, I. S., Farmer, P. E. & Meara, J. G. (2012). Obstructed labor and caesarean delivery: the cost and benefit of surgical intervention.. Plos One, 7 (4), pp.e34595-. https://doi.org/10.1371/journal.pone.0034595.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
BACKGROUND: Although advances in the reduction of maternal mortality have been made, up to 273,000 women will die this year from obstetric etiologies. Obstructed labor (OL), most commonly treated with Caesarean delivery, has been identified as a major contributor to global maternal morbidity and mortality. We used economic and epidemiological modeling to estimate the cost per disability-adjusted life-year (DALY) averted and benefit-cost ratio of treating OL with Caesarean delivery for 49 countries identified as providing an insufficient number of Caesarean deliveries to meet demand. METHODS AND FINDINGS: Using publicly available data and explicit economic assumptions, we estimated that the cost per DALY (3,0,0) averted for providing Caesarean delivery for OL ranged widely, from $251 per DALY averted in Madagascar to $3,462 in Oman. The median cost per DALY averted was $304. Benefit-cost ratios also varied, from 0.6 in Zimbabwe to 69.9 in Gabon. The median benefit-cost ratio calculated was 6.0. The main limitation of this study is an assumption that lack of surgical capacity is the main factor responsible for DALYs from OL. CONCLUSIONS: Using the World Health Organization's cost-effectiveness standards, investing in Caesarean delivery can be considered "highly cost-effective" for 48 of the 49 countries included in this study. Furthermore, in 46 of the 49 included countries, the benefit-cost ratio was greater than 1.0, implying that investment in Caesarean delivery is a viable economic proposition. While Caesarean delivery alone is not sufficient for combating OL, it is necessary, cost-effective by WHO standards, and ultimately economically favorable in the vast majority of countries included in this study.